Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually
- PMID: 29561692
- DOI: 10.1377/hlthaff.2017.1153
Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually
Abstract
Antibiotic-resistant infections are a global health care concern. The Centers for Disease Control and Prevention estimates that 23,000 Americans with these infections die each year. Rising infection rates add to the costs of health care and compromise the quality of medical and surgical procedures provided. Little is known about the national health care costs attributable to treating the infections. Using data from the Medical Expenditure Panel Survey, we estimated the incremental health care costs of treating a resistant infection as well as the total national costs of treating such infections. To our knowledge, this is the first national estimate of the costs for treating the infections. We found that antibiotic resistance added $1,383 to the cost of treating a patient with a bacterial infection. Using our estimate of the number of such infections in 2014, this amounts to a national cost of $2.2 billion annually. The need for innovative new infection prevention programs, antibiotics, and vaccines to prevent and treat antibiotic-resistant infections is an international priority.
Keywords: Cost of Health Care; Health Spending.
Comment in
-
Antibiotic-Resistant Infections: The Authors Reply.Health Aff (Millwood). 2018 Jun;37(6):1015. doi: 10.1377/hlthaff.2018.0551. Health Aff (Millwood). 2018. PMID: 29863930 No abstract available.
-
Identifying Antibiotic-Resistant Infections.Health Aff (Millwood). 2018 Jun;37(6):1014-1015. doi: 10.1377/hlthaff.2018.0550. Health Aff (Millwood). 2018. PMID: 29863932 No abstract available.
Similar articles
-
The economic costs of pain in the United States.J Pain. 2012 Aug;13(8):715-24. doi: 10.1016/j.jpain.2012.03.009. Epub 2012 May 16. J Pain. 2012. PMID: 22607834
-
Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020.Chest. 2015 Jan;147(1):31-45. doi: 10.1378/chest.14-0972. Chest. 2015. PMID: 25058738
-
Economic costs of diabetes in the U.S. In 2007.Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.
-
The Economic and Health-related Impact of Crohn's Disease in the United States: Evidence from a Nationally Representative Survey.Inflamm Bowel Dis. 2016 May;22(5):1032-41. doi: 10.1097/MIB.0000000000000742. Inflamm Bowel Dis. 2016. PMID: 26974852
-
[On the economic burden of MRSA in Germany].Gesundheitswesen. 2014 Dec;76(12):800-6. doi: 10.1055/s-0034-1381987. Epub 2014 Nov 5. Gesundheitswesen. 2014. PMID: 25372655 Review. German.
Cited by
-
CRISPR-Cas9 modified bacteriophage for treatment of Staphylococcus aureus induced osteomyelitis and soft tissue infection.PLoS One. 2019 Nov 22;14(11):e0220421. doi: 10.1371/journal.pone.0220421. eCollection 2019. PLoS One. 2019. PMID: 31756187 Free PMC article.
-
Induction of the Stringent Response Underlies the Antimicrobial Action of Aliphatic Isothiocyanates.Front Microbiol. 2021 Jan 14;11:591802. doi: 10.3389/fmicb.2020.591802. eCollection 2020. Front Microbiol. 2021. PMID: 33584562 Free PMC article.
-
Drug discovery through the isolation of natural products from Burkholderia.Expert Opin Drug Discov. 2021 Jul;16(7):807-822. doi: 10.1080/17460441.2021.1877655. Epub 2021 Jan 29. Expert Opin Drug Discov. 2021. PMID: 33467922 Free PMC article. Review.
-
Antimicrobial stewardship and infection prevention interventions targeting healthcare-associated Clostridioides difficile and carbapenem-resistant Klebsiella pneumoniae infections: a scoping review.BMJ Open. 2021 Aug 4;11(8):e051983. doi: 10.1136/bmjopen-2021-051983. BMJ Open. 2021. PMID: 34348956 Free PMC article.
-
Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial.Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221099729. doi: 10.1177/17534666221099729. Ther Adv Respir Dis. 2022. Retraction in: Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251362671. doi: 10.1177/17534666251362671. PMID: 35657073 Free PMC article. Retracted. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical